

Exhibit 300: Capital Asset Plan and Business Case Summary

Part I: Summary Information And Justification (All Capital Assets)

Section A: Overview (All Capital Assets)

1. **Date of Submission:** 2010-03-19 08:36:30
2. **Agency:** 029
3. **Bureau:** 00
4. **Name of this Investment:** Medical 21st Century HealtheVet Pharmacy-2011
5. **Unique Project (Investment) Identifier:** 029-00-01-11-01-1184-00
6. **What kind of investment will this be in FY 2011?:** Mixed Life Cycle
 - Planning
 - Full Acquisition
 - Operations and Maintenance
 - Mixed Life Cycle
 - Multi-Agency Collaboration
7. **What was the first budget year this investment was submitted to OMB? ***
8. **Provide a brief summary and justification for this investment, including a brief description of how this closes in part or in whole an identified agency performance gap; this description may include links to relevant information which should include relevant GAO reports, and links to relevant findings of independent audits.**

The Pharmacy Re-Engineering and IT Support project (PRE) is intended to address the current and future pharmacy business requirements with new technology by re-engineering, new development and purchase of commercial products. The current suite of pharmacy applications was designed in the mid-80s using dated technology and has become very expensive to maintain and enhance. This project will ultimately replace all existing pharmacy modules and facilitate improved VA pharmacy operations, customer service and patient safety, concurrent with pursuit of full re-engineering of VA pharmacy applications to support a new patient centric business model with a design that is consistent with the proposed HealtheVet architecture. These changes align with the Presidential Management Agenda in the Services for Citizens category under the federal Business Reference Model, with a particular focus on the Health subcategory. The initial increments of the project will address a critical patient safety issue existing in the current system by providing Decision Support Services (DSS) that are expected to reduce Adverse Drug Events by approximately 50%. A COTS product will be used to provide data and services required to support many of these DSS functions. This enhancement is expected to save approximately 115 lives in the first 2 years of implementation. Subsequent enhancements will provide for increased access to benefits by improving formulary management support and improved fiscal performance by reducing 5% in cost of inventory. PRE shares interdependencies with several OMB investments including Lab Reengineering and Medical Legacy.

 - a. **Provide here the date of any approved rebaselining within the past year, the date for the most recent (or planned) alternatives analysis for this investment, and whether this investment has a risk management plan and risk register.**
9. **Did the Agency's Executive/Investment Committee approve this request? ***
 - a. **If "yes," what was the date of this approval? ***
10. **Contact information of Program/Project Manager?**
 - **Name:** *
 - **Phone Number:** *

- Email: *

11. What project management qualifications does the Project Manager have? (per FAC-P/PM)? *

- Project manager has been validated according to FAC-PMPM or DAWIA criteria as qualified for this investment.
- Project manager qualifications according to FAC-P/PM or DAWIA criteria is under review for this investment.
- Project manager assigned to investment, but does not meet requirements according to FAC-P/OM or DAWIA criteria.
- Project manager assigned but qualification status review has not yet started.
- No project manager has yet been assigned to this investment.

12. If this investment is a financial management system, then please fill out the following as reported in the most recent financial systems inventory (FMSI):

Financial management system name(s)	System acronym	Unique Project Identifier (UPI) number
*	*	*

a. If this investment is a financial management system AND the investment is part of the core financial system then select the primary FFMIA compliance area that this investment addresses (choose only one): *

- computer system security requirement;
- internal control system requirement;
- core financial system requirement according to FSIO standards;
- Federal accounting standard;
- U.S. Government Standard General Ledger at the Transaction Level;
- this is a core financial system, but does not address a FFMIA compliance area;
- Not a core financial system; does not need to comply with FFMIA

Section B: Summary of Funding (Budget Authority for Capital Assets)

1.

Table 1: SUMMARY OF FUNDING FOR PROJECT PHASES (REPORTED IN MILLIONS) (Estimates for BY+1 and beyond are for planning purposes only and do not represent budget decisions)									
	PY1 and earlier	PY 2009	CY 2010	BY 2011	BY+1 2012	BY+2 2013	BY+3 2014	BY+4 and beyond	Total
Planning:	*	*	*	*	*	*	*	*	*
Acquisition:	*	*	*	*	*	*	*	*	*
Subtotal Planning & Acquisition:	*	*	*	*	*	*	*	*	*
Operations & Maintenance:	*	*	*	*	*	*	*	*	*
Disposition Costs (optional):	*	*	*	*	*	*	*	*	*
SUBTOTAL:	*	*	*	*	*	*	*	*	*
Government FTE Costs should not be included in the amounts provided above.									
Government FTE Costs	*	*	*	*	*	*	*	*	*
Number of FTE represented by Costs:	*	*	*	*	*	*	*	*	*
TOTAL(including FTE costs)	*	*	*	*	*	*	*	*	*

2. If the summary of funding has changed from the FY 2010 President's Budget request, briefly explain those changes:

*

Section C: Acquisition/Contract Strategy (All Capital Assets)

1.

Table 1: Contracts/Task Orders Table

Contract or Task Order Number	Type of Contract/Task Order (In accordance with FAR Part 16)	Has the contract been awarded (Y/N)	If so what is the date of the award? If not, what is the planned award date?	Start date of Contract/Task Order	End date of Contract/Task Order	Total Value of Contract/Task Order (M)	Is this an Interagency Acquisition? (Y/N)	Is it performance based? (Y/N)	Competitively awarded? (Y/N)	What, if any, alternative financing option is being used? (ESPC, UESC, EUL, N/A)	Is EVM in the contract? (Y/N)
116-10-1005-009/116-C03060 AITC Support	FFP	Y	2009-12-20	2009-12-20	2010-12-20	\$1.0	*	*	*	*	*
116-C93131 Bridge Contract Project Planning	FFP	Y	2009-02-26	2009-03-15	2009-09-30	\$0.6	*	*	*	*	*
116-C93100 Bridge Contract Dev	FFP	Y	2009-02-24	2009-03-15	2009-09-30	\$0.6	*	*	*	*	*
116-C93103 Bridge Contract Testing	FFP	Y	2009-02-24	2009-03-15	2009-09-30	\$0.3	*	*	*	*	*
V200P-1752/PO116-E95101 VCS Application Architecture	FFP	Y	2008-10-01	2008-10-01	2009-09-30	\$0.5	*	*	*	*	*
V200P-1754/PO116-E95126 VCS AS4 Plus Travel	FFP	Y	2008-10-01	2008-10-01	2009-09-30	\$0.2	*	*	*	*	*
V200P-1752/PO116-E95107 VCS PM Plus Travel	FFP	Y	2008-10-01	2008-10-01	2009-09-30	\$0.2	*	*	*	*	*
GS-35F-4363D/116-E95152 VCS SA Plus Travel	FFP	Y	2008-10-01	2008-10-01	2009-09-30	\$0.2	*	*	*	*	*
GS35F-4461G/116-E95162 VCS Technical Writing Support	FFP	Y	2008-10-01	2008-10-01	2009-09-30	\$0.1	*	*	*	*	*
V776P-1133/116-C80251	FFP	Y	2008-09-24	2008-09-24	2009-09-23	\$3.0	*	*	*	*	*
VA 798T-09-RQ-0002 Test Equipment	FFP	Y	2009-08-13	2009-09-13	2009-09-13	\$0.9	*	*	*	*	*
TBD - VCS Replacement Award	FFP	Y	2010-02-04	2010-02-04	2011-02-03	\$6.2	*	*	*	*	*
NNG07DA39B/PO116-E95362	FFP	Y	2009-08-14	2009-08-15	2009-10-12	\$0.9	*	*	*	*	*
116-09-3-9311-0049 Swri Testing	FFP	Y	2009-08-17	2009-08-24	2010-05-23	\$1.0	*	*	*	*	*
Beta Software	FFP	Y	2010-02-26	2010-03-01	2010-04-30	\$0.9	*	*	*	*	*
GS35F0533L/PO116-E95366	FFP	Y	2009-08-17	2009-08-17	2010-08-16	\$0.9	*	*	*	*	*
Enterprise Process Group VCS / 116E95079	FFP	Y	2008-10-01	2008-10-01	2009-09-30	\$0.9	*	*	*	*	*

2. If earned value is not required or will not be a contract requirement for any of the contracts or task orders above, explain why:

*

3. Is there an acquisition plan which reflects the requirements of FAR Subpart 7.1 and has been approved in accordance with agency requirements? *

a. If "yes," what is the date? *

Section D: Performance Information (All Capital Assets)

Table 1: Performance Information Table

Fiscal Year	Strategic Goal(s) Supported	Measurement Area	Measurement Grouping	Measurement Indicator	Baseline	Target	Actual Results
2014	Honor & Memorialize	*	*	Asset and Liability Management: Reduced cost of inventory	FY2005 average inventory level was \$274,571.26	A 5 % decrease in the average inventory level.	To be calculated in Q4 of FY2014.
2011	Ensure Smooth Transition	*	*	Productivity: Decrease in New Service Requests.	FY 2009 service request totaled 86 with the average cost of \$253,000.	New service request will be reduced by 4.	To be calculated in Q1 of FY 2011
2012	Public Health & Socioeconomic Wellbeing	*	*	Data Reliability and Quality: Frequency of National Drug File updates	5 updates were produced in FY2002	Increase the number of updates from 5 updates per year to 52 updates per year.	To be calculated in Q4 of FY2012.
2011	Quality of Life	*	*	Accuracy of service delivered: Decrease in cost of adverse drug events due to improved business process and applied technology.	\$42,460,914 per year	A 10% reduction in cost of ADEs from FY 2005.	To be calculated in Q1 of FY2011.
2012	Honor & Memorialize	*	*	Collection and Receivables: Improved third party collections.	2004 denials currently amount to 80% of all drug claim coding errors.	Denials to be reduced to 50% of all drug claims coding error.	To be calculated in Q4 of FY2012.
2014	Ensure Smooth Transition	*	*	Productivity: Number of prescriptions filled. Improved technology allows greater number of prescriptions to be filled within the same time frame.	There were 105,499,349 prescriptions filled in FY 2002	A 15% increase in prescription fills over the FY2002 baseline.	To be calculated in Q4 2014.
2012	Honor & Memorialize	*	*	Asset and Liability Management	5% Unanticipated Inventory Losses of total inventory.	Unanticipated Inventory Losses of total inventory will be reduced by 1%.	To be calculated in Q4 2012.
2012	Quality of Life	*	*	Accuracy of service delivered: Decrease in cost of adverse drug events due to improved business process and applied technology.	\$42,460,914 per year	A 20% reduction in cost of ADEs from FY 2005.	To be calculated in Q4 of FY2012.

Table 1: Performance Information Table

Fiscal Year	Strategic Goal(s) Supported	Measurement Area	Measurement Grouping	Measurement Indicator	Baseline	Target	Actual Results
2014	Honor & Memorialize	*	*	Collections and Receivables: Improved Third Party collections	2004 denials amount to 80% of all drug claim coding errors.	Denials to be reduced to 25% of all drug claim coding errors.	To be calculated in Q4 of FY2010
2012	Honor & Memorialize	*	*	Productivity: Decrease in New Service Requests.	FY 2009 service request totaled 86 with the average cost of \$253,000.	New service request will be reduced by 10%. Average cost of NSR is \$253,000.	To be calculated in Q4 of 2012.
2014	Ensure Smooth Transition	*	*	Productivity: Decrease in New Service Requests.	FY 2009 service request totaled 86 with the average cost of \$253,000.	New service request will be reduced by 80%. Average cost of NSR is \$253,000.	To be calculated in Q4 of 2014.
2014	Quality of Life	*	*	Accuracy of service delivered: Decrease in cost of adverse drug events due to improved business process and applied technology.	\$42,460,914 per year	A 50% reduction in cost of ADEs.	To be calculated 4th quarter 2014.
2012	Honor & Memorialize	*	*	Efficiency	Non-Formulary drug requests that required pharmacist intervention were 693,240 in FY 2005	An 40% decrease in non-formulary drug requests that require pharmacist intervention. This improvement is in support of Enabling Goal Objective E-3.	To be calculated QTR 4 2012.
2014	Honor & Memorialize	*	*	Efficiency	Non-Formulary drug requests that required pharmacist intervention were 693,240 in FY 2005	An 80% decrease in non-formulary drug requests that require pharmacist intervention. This improvement is in support of Enabling Goal Objective E-3.	To be calculated QTR 4 2014.
2012	Honor & Memorialize	*	*	Efficiency	CMOP utilization was 81.3% in FY 2005	An 8% increase in CMOP fills over the baseline.	To be calculated in Q4 of FY2012.
2012	Honor & Memorialize	*	*	Data Reliability and Quality	Rejections due to non matched items from local drug files to NDF averaged 4K in FY 2005	Non-matched items from local to NDF would be reduced by 30%.	To be calculated in Q4 of FY2012.
2011	Honor & Memorialize	*	*	Efficiency	Non-Formulary drug requests that required	An 20% decrease in non-formulary	To be calculated QTR 1 2011.

Table 1: Performance Information Table

Fiscal Year	Strategic Goal(s) Supported	Measurement Area	Measurement Grouping	Measurement Indicator	Baseline	Target	Actual Results
					pharmacist intervention were 693,240 in FY 2005	drug requests that require pharmacist intervention. This improvement is in support of Enabling Goal Objective E-3.	
2014	Honor & Memorialize	*	*	Efficiency	Current FY 2005 local refill measured at 18.7%	An 8% decrease in local refills. This improvement is in support of Enabling Goal Objective E-3.	To be calculated QTR 4 2014.
2014	Honor & Memorialize	*	*	Efficiency	FY 2005 Dispensing Workload - Number of Inpatient Orders - National is at 13,651,889	A 15% decrease in the number of inpatient orders. This improvement is in support of Enabling Goal Objective E-3.	To be calculated QTR 4 2014.
2014	Honor & Memorialize	*	*	Asset and Liability Management	5% Unanticipated Inventory Losses of total inventory.	Unanticipated Inventory Losses of total inventory will be reduced by 4% over baseline.	To be calculated QTR 4 2014.
2012	Honor & Memorialize	*	*	Data Reliability and quality	FY2005 data indicates in takes 60 to 120 days to match VA data to DoD and CHDR data.	Improvements in the quality of the order checks for shared patients will reduce the number of days to 7 days.	To be calculated in Q4 of FY2012.

Part II: Planning, Acquisition And Performance Information

Section A: Cost and Schedule Performance (All Capital Assets)

1. Comparison of Actual Work Completed and Actual Costs to Current Approved Baseline								
Description of Milestones	Planned Cost (\$M)	Actual Cost (\$M)	Planned Start Date	Actual Start Date	Planned Completion Date	Actual Completion Date	Planned Percent Complete	Actual Percent Complete
PRE V 0.5 Production Development	\$11.7	\$11.7	2007-04-01	2007-04-01	2009-09-29	2009-09-29	93.00%	93.00%
FY 09 Drug Database	\$3.0	\$2.4	2008-10-01	2008-12-24	2009-09-30	2009-12-23	92.00%	92.00%
NWT/NPT	\$16.5	\$0.5	2008-10-01	2008-10-01	2013-09-30		20.00%	3.50%
PMAS PLANNING	\$6.0	\$1.0	2009-08-03	2009-08-03	2010-02-03	2010-02-03	17.00%	17.00%
FY 10 Drug Database	\$3.1	\$2.5	2009-10-01	2009-12-24	2010-09-30		0.00%	0.00%
PRE V 0.5 Testing	\$1.8	\$1.8	2009-10-01	2009-10-01	2010-07-08	2010-06-29	0.00%	0.00%
PRE 2010 Maintenance	\$1.0	\$1.1	2010-01-15	2009-12-30	2010-09-30		0.00%	0.00%
PRE 2010 Development	\$16.1	\$7.3	2010-02-03	2010-02-03	2010-09-30		0.00%	0.00%
PRE V 0.5 Field Testing	\$0.6	\$0.6	2010-05-12	2010-05-12	2010-10-13		0.00%	0.00%
FY 11 Drug Database	*	*	2010-10-01		2011-09-30		0.00%	0.00%
PRE 2011 Development	*	*	2010-10-01		2011-09-30		0.00%	0.00%
PRE 2011 Maintenance	*	*	2010-10-01		2011-09-30		0.00%	0.00%
PRE V 0.5 Deployment	*	*	2010-11-04		2010-12-02		0.00%	0.00%
FY 12 Drug Database	*	*	2011-10-01		2012-09-30		0.00%	0.00%
PRE 2012 Development	*	*	2011-10-01		2012-09-30		0.00%	0.00%
PRE 2012 Maintenance	*	*	2011-10-01		2012-09-30		0.00%	0.00%
PRE 2013 Development	*	*	2012-10-01		2013-09-30		0.00%	0.00%
PRE 2013 Maintenance	*	*	2012-10-01		2013-09-30		0.00%	0.00%
FY 13 Drug Database	*	*	2012-10-01		2013-09-30		0.00%	0.00%
FY 14 Drug Database	*	*	2013-10-01		2014-09-30		0.00%	0.00%
PRE 2014 Development	*	*	2013-10-01		2014-09-30		0.00%	0.00%
PRE 2014 Maintenance	*	*	2013-10-01		2014-09-30		0.00%	0.00%
PRE Post Deployment Maintenance	*	*	2014-10-01		2019-10-30		0.00%	0.00%
PRE V 0.5	\$1.2	\$1.2	2009-05-01	2009-05-01	2009-09-15	2009-09-15	100.00%	100.00%

1. Comparison of Actual Work Completed and Actual Costs to Current Approved Baseline								
Description of Milestones	Planned Cost (\$M)	Actual Cost (\$M)	Planned Start Date	Actual Start Date	Planned Completion Date	Actual Completion Date	Planned Percent Complete	Actual Percent Complete
Test Hardware								
PRE V 0.5 Production Deployment Hardware	\$13.8	\$4.8	2009-07-29	2009-07-29	2010-03-25		13.00%	13.00%
PRE V 1.0 Development	\$3.8	\$3.8	2008-10-01	2008-10-01	2009-08-02	2009-08-02	100.00%	100.00%

* - Indicates data is redacted.